Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Cymbalta Prescribers for Neuropathic Pain (US)(?)

Council Members in this Study Group: 41

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

What is a GLG Leader?
Daniel Wynn, MD, Director, Clinical Research, Consultants In Neurology Ltd.Daniel Wynn, MD
Director, Clinical Research
Consultants In Neurology Ltd.

Daniel Wynn, MD, FACN, FAASM, is a Director of Clinical Research at Consultants in Neurology in Chicago, Illinois. He has expertise in a wide variety of neurological illnesses and has served as a principal investigator in over 100 clinical trials in multiple sclerosis, Alzheimer's disease, stroke, chronic...

Walter Carlini, MD, PhD
Neurologist
Medford Neurological Clinic, Inc.

Walter Carlini, MD, PhD, is a General Neurologist at the Medford Neurological Clinic, Oregon. His clinical interests include stroke, epilepsy, migraine, dementia, movement disorders, and multiple sclerosis. Dr. Carlini has expertise in clinical neurophysiology and in the use of botulinum toxin injections...

Josef Parvizi, MD, Attending Neurologist, Stanford University Medical CenterJosef Parvizi, MD
Attending Neurologist
Stanford University Medical Center

Josef Parvizi, MD, PhD, is an Assistant Professor of Neurological Sciences at Stanford University. Dr. Parvizi has main interest in analyzing the design and results of new clinical trials, of medications or devices, in various fields of neurology. He has clinical expertise in Alzheimer's disease, neuropathic...

Paul Sorell III, MD, FAAPMR
Medical Director
North Shore Pain Specialists

Paul Sorell III, MD, FAAPMR, is the Medical Director of North Shore Pain Specialists, New York. He is also the Director of Pain Medicine at Sun Harbor Manor Residence and a Staff Physician at North Shore University Hospital, and has held offices in numerous other public and private institutions and...

GLG NewsSMAnalyses by this Study Group's Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Novartis and Multiple Sclerosis: A Major Commitment | 06-05-2008
Author: Daniel Wynn, MD, Director, Clinical Research, Consultants In Neurology Ltd.

Extavia, Novartis' brand of  interferon beta 1b, has been approved for the  treatment of multiple sclerosis by the European Union.  With FTY72, Fingolimod, Novartis has the eye on filing NDA by the end of 2009.  While essentially identical to Bayer's Betaferon interferon beta 1b,...

Abbott's ABT-089 --Much More than a Treatment for ADHD | 06-02-2008
Author: Daniel Wynn, MD, Director, Clinical Research, Consultants In Neurology Ltd.

The data on ABT-089 in adults has been released with positive results, whereas the adolescent/childhood trial is on-going for this novel compound for ADHD.  The key difference is the potential to improve learning, not simply regain attention and lessen hyperactivity.

obviously works better | 05-28-2008
Author: GLG Expert Contributor

The info that tekturna HCT works twice as well as HCTZ alone is not earth shattering.  Of course it's better.  That can be said of any HCT/medicine combination

COPAXONE from the START of MS | 04-24-2008
Author: Daniel Wynn, MD, Director, Clinical Research, Consultants In Neurology Ltd.

Copaxone has become the leading treatment for relapsing remitting MS in the US.  The results of the PRECISE trial will likely add to TEVA's sales momentum and boost sales further.

Win for Talecris' Gamunex IVIG in Inflammatory Polyneuropathy | 02-15-2008
Author: Daniel Wynn, MD, Director, Clinical Research, Consultants In Neurology Ltd.

Talecris' form of IVIG, Gamunex was studied in the largest trial of IVIG in chronic inflammatory polyradiculoneuropathy (CIDP), with more than twice as many patients moving into remission.  CIDP is a common acquired autoimmune peripheral neuropathy, which if not treated, may lead to a peripheral...

View All GLG News by members of this Study Group

Most Common Company Types:

  • Office Based Private Practice or Clinic
  • Academic Medical Center/Hospital or Clinic
  • Non-Academic Community Hospital or Clinic

Most Common Job Types:

  • Physician - Attending Physician
  • Owner
  • Physician - Director
  • President
  • Partner
  • Director
  • Physician - Division Head

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics